Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment

Food and Nutrition Research

Volumn 58, Issue , 2014, Pages

  Guzman Rivero, Miguel ^a,b   Rojas, Ernesto ^a   Verduguez Orellana, Aleida ^a   Pardo, Henry ^a   Torrico, Mary Cruz ^a   Cloetens, Lieselotte ^b   Akesson, Björn ^b,c   Sejas, Edgar ^a  

^a UNIVERSIDAD MAYOR DE SAN SIMÓN   (Bolivia)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimony treatment; Clinical chemistry; Cutaneous leishmaniasis; Nutritional biomarkers; Zinc supplementation

Indexed keywords

ANTIMONY; BIOLOGICAL MARKER; GLUCONATE ZINC; MEGLUMINE ANTIMONATE; PLACEBO; TRANSFERRIN RECEPTOR; ZINC;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; NUTRITIONAL STATUS; SKIN DEFECT; SKIN LEISHMANIASIS; VITAMIN SUPPLEMENTATION;

EID: 84915745437     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.3402/fnr.v58.23353     Document Type: Article

References (40)

1. World Health Organization (2010). Control of leishmaniasis: report of a meeting of the WHO expert committee on the control of leishmaniasis. Geneva. http://www.who.int/iris/handle/10665/44412 [cited 19 January 2013].
2. World Health Organization (2010). Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases. http://www.who.int/iris/handle/10665/44440 [cited 19 January 2013].
3. Pan American Health Organization (2013). Leishmaniasis: 2007 update. http-www.paho.org-leishmaniasis [cited 6 June 2013].
4. Salehizadeh E, Nahrevanian H, Farahmand M, Hajihosseini R, Saghiri R, Khalili G. In vivo application of killed leishmania vaccine and imiquimod as adjuvant in Balb/c mice infected with Leishmania major MHRO/IR/75/ER as Iranian strain. Res J Parasitol 2011; 8: 116-26.
5. Rojas E, Parrado R, Delgado R, Reithinger R, Garcia AL. Leishmaniasis in Chaparé, Bolivia. Emerg Infect Dis 2009; 15: 678-80.
6. Bermudez H, Rojas E, Garcia L, Desjeux P, Dujardin J-C, Boelater M, et al. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann Trop Med Parasitol 2006; 100: 591-600.
7. Jones TC, Johnson WDJ, Barretto AC, Lago E, Marsden PD. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis. J Infect Dis 1987; 156: 73-83.
8. Vieira-Gonçalves R, Pirmez C, Jorge ME, Souza WJ, Oliveira MP, Rutowitsch MS, et al. Clinical features of cutaneous and disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Paraty, Rio de Janeiro. Int J Dermatol 2008; 47: 926-32.
9. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis (Review). Cochrane Database Syst Rev 2009; (2): CD004834. doi: 10.1002/14651858.CD004834.pub2.
10. Tulchinsky TH. Micronutrient deficiency conditions: Global health issues. Public Health Rev 2010; 32: 243-55.
11. Taylor CE, Higgs ES. Micronutrients and infectious diseases: thoughts on integration of mechanistic approaches into micronutrient research. J Infect Dis 2000; 182(Suppl 1): S1-4.
12. Amini M, Nahrevanian H, Khatami S, Farahmand M, Mirkhani F, Javadian S. Biochemical association between essential trace elements and susceptibility to Leishmania major in BALB/c and C57BL/6 mice. Braz J Infect Dis 2009; 13: 83-5.
13. Van Weyenbergh J, Santana G, D'Oliveira A, Jr., Santos AF, Jr., Costa CH, Carvalho EM, et al. Zinc/copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infect Dis 2004; 17: 50.
14. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol 2001; 26: 21-6.
15. Prasad AS. Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr 2009; 28: 257-65.
16. Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, et al. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract 2011; 2011: 269515.
17. Torrico-Rojas MC. Manual de normas y procedimientos técnicos de laboratorio para Leishmaniasis. Ministerio de Salud y Deportes Bolivia; 2010. La Paz Bolivia. ISBN:978-99954-50-13-7.
18. Bermúdez H, Solano M, Torrico-Rojas MC, Carballo-Montero M, Lafuente-Covarrubias O, Lara-Arias MP, et al. Diagnostico de leishmaniasis utilizando medio de cultivo TSTB en pacientes del tropico de Cochabamba. Gac Med Bol 2005; 28: 31-5.
19. Oliveira AGL, Brito PD, Schubach AO, Oliveira RV, Saheki MN, Lyra MR, et al. Influence of the nutritional status in the clinical and therapeutical evolution in adults and elderly with American Tegumentary Leishmaniasis. Acta Trop 2013; 128: 36-40.
20. Maciel BL, Lacerda HG, Queiroz JW, Galvão J, Pontes NN, Dimenstein R, et al. Association of nutritional status with the response to infection with Leishmania chagasi. Am J Trop Med Hyg 2008; 79: 591-8.
21. Baynes RD. Assessment of iron status. Clin Biochem 1996; 29: 209-15.
22. Shaw JG, Friedman JF. Iron deficiency anemia: focus in infectious diseases in lesser developed countries. Anemia 2011; 2011: 260380.
23. Kumar V, Choudhry VP. Iron deficiency and infections. Indian J Pediatr 2010; 77: 789-93.
24. Machado-Coelho GL, Caiaffa WT, Genaro O, Magalhães PA, Mayrink W. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2005; 99: 55-61.
25. Lal CS, Kumar S, Ranjan A, Rabidas VN, Verma N, Pandey K, et al. Comparative analysis of serum zinc, copper, magnesium calcium and iron level in acute and chronic patients of visceral leishmaniasis. J Trace Elem Med Biol 2013; 27: 98-102.
26. Sharquie KE, Najim RA, Farjou IB. A comparative controlled trial of intralesionally-Administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol 1997; 22: 169-73.
27. Iraji F, Vali A, Shahtalebi AM, Momeni AZ. Comparison of intralesionally injected zinc sulphate with meglumine antimoniate in treatment of acute cutaneous leishmaniasis. Dermatology 2004; 209: 46-9.
28. Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, et al. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 2013; 56: 1255-60.
29. Burns JL, Mancoll JS, Phillips LG. Impairments to wound healing. Clin Plast Surg 2003; 30: 47-56.
30. Harris CL, Fraser C. Malnutrition in the institutionalized elderly: the effect on wound healing. Ostomy Wound Manage 2004; 50: 54-63.
31. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res 2010; 89: 219-29.
32. Zambrano-Villa S, Rosales-Borjas D, Carrero JC, Ortiz-Ortiz L. How protozoan parasites evade the immune response. Trends Parasitol 2002; 18: 272-8.
33. Bogdan C, Röllinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 1998; 28: 121-34.
34. Ansari NA, Sharma P, Salotra P. Circulating nitric oxide and C-reactive protein levels in Indian Kala azar patients: correlation with clinical outcome. Clin Immunol 2007; 122: 343-8.
35. Paltrineri S, Ravicini S, Rossi G, Roura X. Serum concentration of the derivatives of reactive oxygen metabolites (d-ROMs) in dogs with leishmaniosis. Vet J 2010; 186: 393-5.
36. Wasunna KM, Raynes JG, Were JB, Muigai R, Sherwood J, Gachihi G, et al. Acute phase protein concentrations predict parasite clearance rate during therapy for visceral leishmaniasis. Trans R Soc Trop Med Hyg 1995; 89: 678-81.
37. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113: 934-40.
38. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 2011; 118: 87-96.
39. Soto J, Valda-Rodriguez L, Toledo J, Vera-Navarro L, Luz M, Monasterios-Torrico H, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg 2004; 71: 577-81.
40. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103: 33-40.